Russell Investments Group Ltd. Trims Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Russell Investments Group Ltd. lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 405,279 shares of the company's stock after selling 8,564 shares during the quarter. Russell Investments Group Ltd. owned about 0.41% of Neurocrine Biosciences worth $53,402,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Truist Financial Corp lifted its stake in Neurocrine Biosciences by 4.0% in the 4th quarter. Truist Financial Corp now owns 37,195 shares of the company's stock worth $4,901,000 after purchasing an additional 1,423 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Neurocrine Biosciences by 3.6% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,048 shares of the company's stock worth $402,000 after purchasing an additional 107 shares during the last quarter. GAMMA Investing LLC purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth about $119,000. Linden Thomas Advisory Services LLC boosted its stake in Neurocrine Biosciences by 3.6% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 6,456 shares of the company's stock valued at $851,000 after buying an additional 225 shares during the last quarter. Finally, Larson Financial Group LLC grew its holdings in Neurocrine Biosciences by 20,418.2% during the 4th quarter. Larson Financial Group LLC now owns 2,257 shares of the company's stock valued at $297,000 after buying an additional 2,246 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $140.00, for a total value of $28,000.00. Following the transaction, the insider now owns 7,507 shares in the company, valued at $1,050,980. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock in a transaction on Monday, March 11th. The shares were sold at an average price of $140.00, for a total value of $28,000.00. Following the transaction, the insider now directly owns 7,507 shares of the company's stock, valued at $1,050,980. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Benevich sold 75,000 shares of the company's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00. Following the transaction, the insider now directly owns 40,778 shares in the company, valued at $5,683,637.64. The disclosure for this sale can be found here. Insiders sold 186,994 shares of company stock worth $25,806,409 in the last three months. 4.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

NBIX has been the topic of several recent research reports. Wells Fargo & Company raised Neurocrine Biosciences from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $140.00 to $170.00 in a report on Wednesday, April 24th. Citigroup lowered their price objective on Neurocrine Biosciences from $141.00 to $140.00 and set a "neutral" rating for the company in a research note on Thursday, February 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. Wedbush restated an "outperform" rating and set a $147.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 17th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $150.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $142.38.

Neurocrine Biosciences Trading Up 2.1 %

Shares of NBIX traded up $2.90 during mid-day trading on Monday, hitting $138.89. The company's stock had a trading volume of 681,740 shares, compared to its average volume of 845,887. The company's 50-day moving average is $136.76 and its 200-day moving average is $128.24. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37. The firm has a market capitalization of $13.82 billion, a price-to-earnings ratio of 57.39 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. Neurocrine Biosciences's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.88 earnings per share. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.8 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.